Semax
ACTH(4-10) analogue · Met-Glu-His-Phe-Pro-Gly-Pro
Russian-approved nootropic and neuroprotective nasal peptide; minimal research outside Russia.
Not FDA-approved. Approved in Russia and some CIS countries. Not approved by FDA or EMA. This page describes research and public discussion; it is not a recommendation to use.
Overview
Semax is a synthetic heptapeptide based on a fragment of ACTH, with no hormonal activity. It is on Russia's essential medicines list for stroke and cognitive disorders. Most studies are Russian-language with small samples.
Mechanism of action
Increases BDNF and its receptor TrkB, modulates dopaminergic and serotonergic signaling, and affects inflammatory gene expression after ischemia (animal data).
Benefits & evidence ratings
Dosing
Doses show what has been studied or discussed — not guidance. Always follow your prescriber.
| Source | Dose | Frequency | Duration | Route |
|---|---|---|---|---|
Russian label (stroke, 1% solution) B Human clinical data | Up to 6,000 mcg/day split doses | Daily | 10–14 days | Intranasal |
Russian label (cognitive, 0.1%) B Human clinical data | 200–900 mcg/day | Daily | 5–14 days | Intranasal |
Online protocols D Anecdotal / community | 300–600 mcg | Daily | Cycles of 2–4 weeks | Intranasal |
Clinical trials & studies
- Human studyVariousSemax in acute ischemic stroke
Russian clinical studies of neurological recovery.
- Animal2006Semax and BDNF expression (rat hippocampus)
Increased BDNF and TrkB.
Safety
Side effects
- Nasal irritation
- Rare: anxiety, irritability
Contraindications
- Acute psychosis
- Seizure disorders (caution)
- Pregnancy
Interactions
- Stimulants (additive)
Long-term safety
Poorly characterized outside short courses.
Regulatory status
Approved outside US
Approved in Russia and some CIS countries. Not approved by FDA or EMA.
FAQ
Commonly discussed alongside
Listing a combination does not mean it has been studied or is safe.